Migraine Headache: Updates and Future Developments

Parker E. Bohm, Fernando F. Stancampiano, Todd Rozen

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Migraine is a common disabling condition that is frequently managed by primary care providers. In recent years, the growing array of migraine therapies has added complexity to patient care. This article serves as a succinct review of pertinent updates and future directions regarding migraine. Our understanding of pathophysiology has progressed along with new advances in biomarkers and genetics. These discoveries have led to a wealth of new options for treatment, many of which are specifically targeted against molecules implicated in migraine headache such as calcitonin gene–related peptide. These treatments include several monoclonal antibodies, calcitonin-gene related peptide receptor antagonists, and 5-hydroxytryptamine 1F (5-HT1F) receptor agonists; new options such as these are important for the large population falling out of eligibility for triptans. Furthermore, various nonpharmacological options including noninvasive brain stimulation have joined the arsenal of therapies used for treating migraine.

Original languageEnglish (US)
Pages (from-to)1648-1653
Number of pages6
JournalMayo Clinic Proceedings
Volume93
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Migraine Disorders
Calcitonin Gene-Related Peptide Receptors
Tryptamines
Serotonin Receptors
Calcitonin
Managed Care Programs
Therapeutics
Primary Health Care
Patient Care
Biomarkers
Monoclonal Antibodies
Peptides
Brain
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Migraine Headache : Updates and Future Developments. / Bohm, Parker E.; Stancampiano, Fernando F.; Rozen, Todd.

In: Mayo Clinic Proceedings, Vol. 93, No. 11, 01.11.2018, p. 1648-1653.

Research output: Contribution to journalReview article

Bohm, Parker E. ; Stancampiano, Fernando F. ; Rozen, Todd. / Migraine Headache : Updates and Future Developments. In: Mayo Clinic Proceedings. 2018 ; Vol. 93, No. 11. pp. 1648-1653.
@article{3b09a470c3304422980c0fd7acc9cedc,
title = "Migraine Headache: Updates and Future Developments",
abstract = "Migraine is a common disabling condition that is frequently managed by primary care providers. In recent years, the growing array of migraine therapies has added complexity to patient care. This article serves as a succinct review of pertinent updates and future directions regarding migraine. Our understanding of pathophysiology has progressed along with new advances in biomarkers and genetics. These discoveries have led to a wealth of new options for treatment, many of which are specifically targeted against molecules implicated in migraine headache such as calcitonin gene–related peptide. These treatments include several monoclonal antibodies, calcitonin-gene related peptide receptor antagonists, and 5-hydroxytryptamine 1F (5-HT1F) receptor agonists; new options such as these are important for the large population falling out of eligibility for triptans. Furthermore, various nonpharmacological options including noninvasive brain stimulation have joined the arsenal of therapies used for treating migraine.",
author = "Bohm, {Parker E.} and Stancampiano, {Fernando F.} and Todd Rozen",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.mayocp.2018.09.006",
language = "English (US)",
volume = "93",
pages = "1648--1653",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - Migraine Headache

T2 - Updates and Future Developments

AU - Bohm, Parker E.

AU - Stancampiano, Fernando F.

AU - Rozen, Todd

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Migraine is a common disabling condition that is frequently managed by primary care providers. In recent years, the growing array of migraine therapies has added complexity to patient care. This article serves as a succinct review of pertinent updates and future directions regarding migraine. Our understanding of pathophysiology has progressed along with new advances in biomarkers and genetics. These discoveries have led to a wealth of new options for treatment, many of which are specifically targeted against molecules implicated in migraine headache such as calcitonin gene–related peptide. These treatments include several monoclonal antibodies, calcitonin-gene related peptide receptor antagonists, and 5-hydroxytryptamine 1F (5-HT1F) receptor agonists; new options such as these are important for the large population falling out of eligibility for triptans. Furthermore, various nonpharmacological options including noninvasive brain stimulation have joined the arsenal of therapies used for treating migraine.

AB - Migraine is a common disabling condition that is frequently managed by primary care providers. In recent years, the growing array of migraine therapies has added complexity to patient care. This article serves as a succinct review of pertinent updates and future directions regarding migraine. Our understanding of pathophysiology has progressed along with new advances in biomarkers and genetics. These discoveries have led to a wealth of new options for treatment, many of which are specifically targeted against molecules implicated in migraine headache such as calcitonin gene–related peptide. These treatments include several monoclonal antibodies, calcitonin-gene related peptide receptor antagonists, and 5-hydroxytryptamine 1F (5-HT1F) receptor agonists; new options such as these are important for the large population falling out of eligibility for triptans. Furthermore, various nonpharmacological options including noninvasive brain stimulation have joined the arsenal of therapies used for treating migraine.

UR - http://www.scopus.com/inward/record.url?scp=85055722152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055722152&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.09.006

DO - 10.1016/j.mayocp.2018.09.006

M3 - Review article

C2 - 30392545

AN - SCOPUS:85055722152

VL - 93

SP - 1648

EP - 1653

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -